neuromyelitis


Also found in: Dictionary, Medical.
Related to neuromyelitis: neuromyelitis optica

neuromyelitis

[¦nu̇r·ō‚mī·ə′līd·əs]
(medicine)
Inflammation of the spinal cord and of nerves.
Mentioned in ?
References in periodicals archive ?
- Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder
Impact of eculizumab on hospitalization rates and relapse treatment in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study.
* SOLIRIS - Neuromyelitis Optica Spectrum Disorder (NMOSD): In June 2019, the U.S.
The US Food and Drug Administration approved SOLIRIS (eculizumab) for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) in adult patients who are anti-aquaporin-4 antibody positive on June 27, 2019.
The US Food and Drug Administration (FDA) on Thursday authorised the marketing of Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive, under its priority review.
The neurological disorders segment has been classified into chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, multiple sclerosis, neuromyelitis optica, and Guillain-Barre syndrome.
It frequently forms part of a neuromyelitis optica spectrum disorder (NMOSD) associated with the presence of the autoantibody anti-aquaporin 4 (AQP4).
Optic neuritis (ON) is an inflammatory disease of the optic nerve characterized by painful visual loss, and it is usually associated with multiple sclerosis (MS), or neuromyelitis optica spectrum disorders (NMOSD).
This includes multiple sclerosis and an array of brain and spinal cord conditions such as neuromyelitis optica.
WHEREAS, some rare diseases and disorders, such as Lou Gehrigs disease, also known as amyotrophic lateral sclerosis (ALS), are relatively well known because of successful awareness campaigns, many are not, such as Neuromyelitis Optica Spectrum disorder (NMOSD), which affects the optic nerves and spinal cord, causing pain and vision loss, which leads to weakness, numbness, and sometimes paralysis of all four limbs; and
As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as the first and only approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS) and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG), and is also developing it for patients with neuromyelitis optica spectrum disorder (NMOSD).